Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

merit medical systems inc. - MMSI

MMSI

Close Chg Chg %
70.57 -0.03 -0.04%

Closed Market

70.54

-0.03 (0.04%)

Volume: 570.24K

Last Updated:

Apr 14, 2026, 4:00 PM EDT

Trade Now

Company Overview: merit medical systems inc. - MMSI

MMSI Key Data

Open

$70.60

 Day Range

70.13 - 71.59

52 Week Range

66.34 - 100.09

 Market Cap

$4.19B

Shares Outstanding

59.43M

 Public Float

58.01M

Beta

0.64

 Rev. Per Employee

N/A

P/E Ratio

33.21

 EPS

$2.17

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

773.16K

  

MMSI Performance

1 Week
 
 3.38%
 
1 Month
 
 0.89%
 
3 Months
 
 -14.26%
 
1 Year
 
 -23.33%
 
5 Years
 
 14.23%
 

MMSI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About merit medical systems inc. - MMSI

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

MMSI At a Glance

Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, Utah 84095
Phone 1-801-253-1600 Revenue 1.51B
Industry Medical Specialties Net Income 128.49M
Sector Health Technology 2025 Sales Growth 11.84%
Fiscal Year-end 12 / 2026 Employees 7,500
View SEC Filings

MMSI Valuation

P/E Current 32.119
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 41.474
Price to Sales Ratio 3.518
Price to Book Ratio 3.306
Price to Cash Flow Ratio 17.92
Enterprise Value to EBITDA 17.873
Enterprise Value to Sales 3.764
Total Debt to Enterprise Value 0.144

MMSI Efficiency

Revenue/Employee 201,964.00
Income Per Employee 17,131.867
Receivables Turnover 6.774
Total Asset Turnover 0.593

MMSI Liquidity

Current Ratio 4.338
Quick Ratio 2.946
Cash Ratio 1.871

MMSI Profitability

Gross Margin 48.652
Operating Margin 12.172
Pretax Margin 11.285
Net Margin 8.483
Return on Assets 5.034
Return on Equity 8.671
Return on Total Capital 5.341
Return on Invested Capital 5.637

MMSI Capital Structure

Total Debt to Total Equity 51.857
Total Debt to Total Capital 34.149
Total Debt to Total Assets 30.588
Long-Term Debt to Equity 51.171
Long-Term Debt to Total Capital 33.697
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Merit Medical Systems Inc. - MMSI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.15B 1.25B 1.35B 1.51B
Sales Growth
+6.21% +9.23% +8.07% +11.84%
Cost of Goods Sold (COGS) incl D&A
678.85M 731.05M 713.83M 777.79M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
92.20M 101.29M 114.73M 134.65M
Depreciation
43.80M 45.19M 49.13M 49.55M
Amortization of Intangibles
48.40M 56.10M 65.60M 85.10M
COGS Growth
+6.06% +7.69% -2.36% +8.96%
Gross Income
468.55M 522.23M 640.55M 736.94M
Gross Income Growth
+6.41% +11.46% +22.66% +15.05%
Gross Profit Margin
+40.84% +41.67% +47.29% +48.65%
2022 2023 2024 2025 5-year trend
SG&A Expense
369.63M 400.30M 484.10M 552.57M
Research & Development
75.51M 82.73M 87.47M 97.35M
Other SG&A
294.13M 317.58M 396.63M 455.21M
SGA Growth
+3.42% +8.30% +20.93% +14.14%
Other Operating Expense
- - - -
-
Unusual Expense
12.58M 1.52M 1.58M 1.09M
EBIT after Unusual Expense
86.34M 120.41M 154.87M 183.29M
Non Operating Income/Expense
2.62M 9.74M 28.00M 14.11M
Non-Operating Interest Income
439.00K 2.46M 26.23M 15.07M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
6.33M 18.06M 32.88M 26.46M
Interest Expense Growth
+68.63% +185.46% +82.02% -19.51%
Gross Interest Expense
6.33M 18.06M 32.88M 26.46M
Interest Capitalized
- - - -
-
Pretax Income
82.63M 112.09M 149.99M 170.94M
Pretax Income Growth
+53.25% +35.65% +33.82% +13.96%
Pretax Margin
+7.20% +8.94% +11.07% +11.28%
Income Tax
8.11M 17.68M 29.64M 42.45M
Income Tax - Current - Domestic
12.75M 19.46M 31.35M 22.61M
Income Tax - Current - Foreign
10.29M 10.86M 13.16M 14.63M
Income Tax - Deferred - Domestic
(14.05M) (12.73M) (14.03M) 5.14M
Income Tax - Deferred - Foreign
(871.00K) 86.00K (843.00K) 70.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
74.52M 94.41M 120.36M 128.49M
Minority Interest Expense
- - - -
-
Net Income
74.52M 94.41M 120.36M 128.49M
Net Income Growth
+53.79% +26.70% +27.48% +6.76%
Net Margin Growth
+6.49% +7.53% +8.89% +8.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
74.52M 94.41M 120.36M 128.49M
Preferred Dividends
- - - -
-
Net Income Available to Common
74.52M 94.41M 120.36M 128.49M
EPS (Basic)
1.3118 1.6393 2.0673 2.172
EPS (Basic) Growth
+52.00% +24.97% +26.11% +5.06%
Basic Shares Outstanding
56.81M 57.59M 58.22M 59.16M
EPS (Diluted)
1.2921 1.6178 2.0274 2.1252
EPS (Diluted) Growth
+52.95% +25.21% +25.32% +4.82%
Diluted Shares Outstanding
57.67M 58.36M 59.37M 60.46M
EBITDA
191.12M 223.22M 271.18M 319.03M
EBITDA Growth
+6.96% +16.80% +21.49% +17.64%
EBITDA Margin
+16.66% +17.81% +20.02% +21.06%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 101.182
Number of Ratings 12 Current Quarters Estimate 1.057
FY Report Date 06 / 2026 Current Year's Estimate 4.037
Last Quarter’s Earnings 0.835 Median PE on CY Estimate N/A
Year Ago Earnings 3.83 Next Fiscal Year Estimate 4.399
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 10 10
Mean Estimate 1.06 1.03 4.04 4.40
High Estimates 1.10 1.06 4.08 4.52
Low Estimate 1.01 1.00 3.97 4.28
Coefficient of Variance 3.06 2.05 1.06 1.80

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 7 7
OVERWEIGHT 2 2 3
HOLD 2 2 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Merit Medical Systems Inc. - MMSI

Date Name Shares Transaction Value
Mar 3, 2026 Michel J. Voigt CHIEF HUMAN RESOURCES OFFICER 29,414 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Christian Adam Smith Chief Commercial Officer 19,181 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Neil W. Peterson CHIEF OPERATING OFFICER 47,000 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $78.02 per share 3,666,940.00
Mar 3, 2026 Neil W. Peterson CHIEF OPERATING OFFICER 53,061 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Neil W. Peterson CHIEF OPERATING OFFICER 36,059 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Christian Adam Smith Chief Commercial Officer 25,590 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Christian Adam Smith Chief Commercial Officer 32,352 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Christian Adam Smith Chief Commercial Officer 30,334 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $78.02 per share 2,366,658.68
Mar 3, 2026 Michel J. Voigt CHIEF HUMAN RESOURCES OFFICER 46,127 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $78.02 per share 3,598,828.54
Mar 3, 2026 Michel J. Voigt CHIEF HUMAN RESOURCES OFFICER 52,825 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Michel J. Voigt CHIEF HUMAN RESOURCES OFFICER 35,823 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Raul Parra CFO AND TREASURER 57,343 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $78.02 per share 4,473,900.86
Mar 3, 2026 Raul Parra CFO AND TREASURER 63,121 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Raul Parra CFO AND TREASURER 46,119 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Raul Parra CFO AND TREASURER 36,506 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 62,132 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $78.02 per share 4,847,538.64
Mar 3, 2026 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 67,910 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 50,908 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Brian Glen Lloyd CHIEF LEGAL OFFICER, SECRETARY 44,499 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2026 Martha Goldberg Aronson President and CEO; Director 47,792 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Merit Medical Systems Inc. in the News